Pharmacological Reports , 2018 Neurological and NO Pathway Regulation: Emerging data suggests that BPC-157 may modulate nitric oxide (NO) and dopamine systems, which could explain its potential for nerve regeneration and mood regulationthough lower doses may be more appropriate for systemic neurological use
Therefore, it is controversial whether GLP-1RAs therapy could prevent and treat diabetic osteoporosis and fragility fractures in clinical practice
Besides, BPC 157 therapy effects described in rats with bile duct cirrhosis and portal hypertension resulted in much less Ki-67- and alpha smooth muscle actin (-SMA) staining, counteracted disturbed cell proliferation and cytoskeletal structure in hepatic stellate cells, and showed a less disturbed collagen presentation, and thereby, less Mallory staining, and more hepatocytes where fewer had double nuclei[25]
L., Fetherston, J
It is important to distinguish between different types of hair loss: Telogen effluvium : A temporary condition where hair follicles prematurely enter the resting (telogen) phase, leading to diffuse hair shedding 23 months after a triggering event [23] Androgenetic alopecia : Pattern hair loss related to genetic and hormonal factors Alopecia areata : An autoimmune condition causing patchy hair loss The hair changes reported with GLP-1 use most commonly resemble telogen effluvium , characterised by diffuse thinning rather than discrete bald patches
